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1. INTRODUCTION 
1.1 Introduction to High-Performance Liquid Chromatography (HPLC) 
High-performance liquid chromatography (HPLC) is an advanced form of liquid 
chromatography used in separating the complex mixture of molecules encountered in 
chemical and biological systems, in order to understand better the role of individual 
molecules. Among different chromatographic methods, high performance liquid 
chromatography (HPLC) offers a greater variety of stationary phases, which there by allows 
selective interactions and more possibilities for separation. In HPLC the separation is about 
100 times faster than the conventional liquid chromatography due to packing of particles in 
the range of 3-10 m. In HPLC mobile phase composition is changed in a programmed fashion 
to increase the efficiency of separation. 
Depending on the unique affinity of each component (referred to as the analyte) 
between the mobile phase and the stationary phase, each analyte migrates along the column at 
different speeds and emerges from the column at different times, thus establishing a 
separation of the mixture. Analytes with higher affinity for the mobile phase migrate faster 
down the column, whereas those with higher affinity for the stationary phase migrate slower. 
This migration time (referred to as retention time) is unique for each analyte and can be used 
in its identification. With the appropriate use of a detection method after the column, each 
analyte can also be quantified for analysis. 
Smaller column particle size can improve chromatographic resolution, but increased 
solvent delivery pressure is needed. Further reduction of column particle size can allow for 
higher solvent flow rates, reducing analysis time without sacrificing resolution. 
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1.1.1 Advantages and limitations of HPLC  
Table 1 highlights the Advantages and limitations of HPLC. HPLC is highly efficient 
separation technique used for multi component analysis of real life samples and complex 
mixtures.  
Table 1: Advantages and limitations of HPLC 
 
Advantages   
 High resolution and speed of analysis.  
 Can be used for separation and analysis of complex mixtures.  
 A variety of solvents and column packing’s are available, 
      providing a high degree of selectivity for specific analysis.  
 Easy automation of instrument operation and data analysis.  
 Adaptability to large scale pre operative procedures  
 High sensitivity detection 
 Quantitative sample recovery 
 Greater accuracy and precise. 
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Limitations 
 Less separation efficiency than capillary GC 
 No universal detector 
 More difficult for novices 
 
1.1.2 Types of HPLC Techniques 
 Based on modes of chromatography: 
 Reverse phase chromatography  
 Normal phase chromatography  
 Based on principle of separation:  
 Affinity chromatography  
 Size exclusion chromatography  
 Adsorption chromatography  
 Ion exchange chromatography  
 Chiral phase chromatography  
 Based on the scale of operation:  
 Analytical HPLC  
 Preparative HPLC  
 Base on elution technique:  
 Gradient separation  
 Isocratic separation  
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1.1.3 Classification of Chromatographic methods: 
                          Table 2: classification of chromatographic methods 
Mobile phase Stationary phase Method 
 
Liquid 
 
 
Solid 
 
Adsorption column, thin-layer, 
ion exchange, High performance 
liquid chromatography. 
Liquid 
 
 
Gas 
 
Liquid 
 
Partition, column, thin-layer, 
HPLC, paper chromatography. 
 
Gas – Liquid Chromatography. 
1.2 Method development: 
Developing and validating an analytical method is very expensive, before developing new 
method, a thorough literature survey should be conducted for existing methodologies of 
intended analyte or similar molecules. Survey conducted by using chemical abstracts, 
compendial monographs (USP, EP), journal articles, internet, manufacturer literature. 
New analytical methods are required for following reasons. 
 Existing method are not available. 
 Technique has better performance like easy of use, highly sensitive, rapid turnaround or new 
instrumentation. 
 An alternate method required for regulatory compliance. 
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 Existing method are not sufficiently reliable, sensitive, or cost effective. 
1.2.1 Strategy for method development 
Commonly involved steps in strategy for method development: 
Description of method and separation goals 
 
Collection of sample and analyte information 
 
Initial method development 
 
Method tuning – optimization 
  
Method validation 
1.2.2 Method goals 
Analytical method goals in turn defined as, method acceptance criteria for peak area %RSD, 
linearity range, and various system suitability parameters like, resolution, tailing factor, 
precision of retention time, specificity, sensitivity. 
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Table 3: Acceptance criteria for system suitability parameters 
parameter acceptance criteria 
retention time analysis time 5-30 min 
%RSD < 2% 
resolution >2 
tailing factor NMT 2 
Other desirable characteristics include: 
 Minimal sample work up 
 Robust method that does not require extensive training for execution 
 Low cost per analysis 
1.2.3 Method types 
HPLC methods are developed for single analyte and multiple analyte assays. Methods can be 
divided in to three major categories. 
 Qualitative 
 Quantitative 
 Preparative 
a) Qualitative method 
It is an identification test that conforms the presence or absence of analyte in the sample by 
matching retention time with that of reference standard. 
b) Quantitative method 
Quantitative method mainly gives the information related to concentration of analyte in the 
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sample. Quantitative method can also considered as qualitative method, an assay method can 
often also serve as an identification method. Developing a quantitative method is more 
difficult and requires greater effort for validation than developing qualitative method. 
c) Preparative method 
Preparative method is used to isolate the purified component in the sample. Method validation 
is not required in this process because, this method mainly meant for generate purified 
components. 
1.2.4 Steps involved in development of HPLC method: 
a) Literature survey 
It is helpful to avoid duplication of work 
It gives important information of sample to be considered during method development 
 Pka value of compound 
 Nature of sample matrix 
 UV spectrum of compound 
 Number of compounds presents 
 Sample solubility 
 Sample stability 
 Chemical nature of sample 
 Chemical structure of compound 
 Concentration range of compounds in sample interest 
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b) Selection of chromatographic method 
Primarily normal phase chromatographic method should be tried. If it is not produce reliable 
results then go for reverse phase chromatographic method. 
For ion exchange or ion pair chromatography, first ion suppression by pH control and 
reversed phase chromatography should be tried. 
c) Selection of stationary phase 
Based on polarity and affinity of analyte towards the stationary phase the column was 
selected. 
d) Selection of mobile phase 
Reversed phase bonded packing, when used in conjunction with highly polar solvents. 
Mobile phase may be either single liquid or combination of liquids, which are compatible 
with sample, column and instrument. 
Initial experimental conditions for separation in HPLC: 
Table: 4 Initial experimental conditions for separation in HPLC 
Separation variable Initial choice 
 
Column 
Dimensions 
Particle size 
Stationary phase 
15 (or 25) x 0.46 cm 
5 or 3.5 μm 
C – 18 or C – 8 or phenyl 
 
 
Mobile Phase 
Solvent A/B 
%B 
Buffer compound, 
Water(or aqueous buffer)/ acetonitrile 
Variable 
25 mM phosphate, 
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PH Conc. 
Additives 
Flow rate 
pH ≤ 3.5 
25 – 50 mM Triethylamine (TEA) 
1 – 2 mL/min 
Temperature  40ºC 
 
Sample size 
Volume 
Mass 
≤ 50μL 
≤ 100μg 
Based on Sample Characteristics different buffer solutions has been selected 
Table: 5 recommended additives for reversed phase HPLC 
Sample Characteristics  Additives 
Basic compounds (e.g. amines) 
 
50 mM phosphate buffer, 30 mM 
triethylamine(buffer pH-3.0) 
Acidic compounds (e.g. carboxylic acids)  50 mM phosphate buffer, 1% acetic 
acid (buffer pH-3.0) 
Mixture of acids and bases (buffer pH – 3.0)  
 
50 mM phosphate buffer, 30 mM 
triethylamine, 1% acetic acid 
Cationic salts (e.g. tetra alkyl quaternary 
ammonium compounds) 
 30 mM triethylamine, 50 mM sodium 
nitrate 
 
Anionic salts 
 1% acetic acid, 50 mM sodium 
nitrate. 
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e) Selection of suitable detector  
Detector is the major part of HPLC system and measures the compounds after their 
separation on the column.  
There are basically two types of detectors. 
 Bulk property detector 
 Solute property detectors 
UV detector is the first choice because of its convenience and applicability in case of most of 
the samples. The latest version of equipments is available with photo diode - array detectors 
(PDA or DAD).  
Different variables like organic solvent, mobile phase, solvent strength, column type, column 
temperature, concentration of mobile phase additives may show different effect in results or 
response. These variables used to vary band spacing. 
Table 6.Variables used to vary band spacing 
Variable Comment 
Choice of organic solvent A change from methanol to acetonitrile or 
THF often results in large changes in 
separation. 
Mobile phase A change in pH may result in a major 
effect on band spacing for samples that 
contain ionic or ionisable compounds. 
Solvent strength A change in percent organic often provides 
significant changes in retention and 
separation. 
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Column type This refers to the choice of bonded-phases 
for reversed-phase LC (C – 18, C – 8, 
phenyl, cyano, trimethyl, etc.,) 
Concentration of mobile phase additives The most common additives for varying 
band spacing include amine modifiers, acid 
modifiers, buffers and salts 
Temperature Temperatures of 25 - 60º C are more 
common. 
1.3 Method Validation 
Guidelines provide frame work for validation of developed method. 
For pharmaceutical methods guidelines prescribed by, 
 United states pharmacopoeia 
 World health organization 
 Food and drug administration 
 International conference on harmonization 
1.3.1 United states pharmacopoeia (USP) 
As per USP, validation is defined as “the process by which it is establish by laboratory 
studies the performance characteristics of the method meet the requirement for intended 
analytical application”. 
1.3.2 World health organization (WHO) 
As per WHO, validation is defined as “the process of providing documented evidences that a 
system / procedure dose what it is supposed to do precisely and reliably”. 
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1.3.3 Food and drug administration (FDA) 
As per FDA validation is defined as “establishing documented evidence, which provides a 
high degree of assurance that a specific process will consistently produce meeting it pre 
determined specifications and quality attributes”.  
1.3.4 International conference on harmonization 
As per ICH, validation is defined as establishing documented evidence, which provides a 
high degree of assurance that a specific process will consistently produce meeting it pre 
determined specifications and quality attributes”.  
1.3.5 Different regulatory validation parameters 
Different regulatory bodies like ICH, FDA, GMP, USP provides validation parameters 
 USP validation parameters 
 FDA validation parameters 
 GMP validation parameters 
 ICH validation parameters 
USP validation parameters 
 Specificity  
 Linearity& ( Range ) 
 Accuracy 
 Precision 
 Limit of detection  
 Limit of quantification 
 Ruggedness 
 Robustness 
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FDA validation parameters: 
 Specificity  
 Linearity & (Range) 
 Accuracy 
 Precision 
 Recovery 
 Ruggedness 
GMP validation parameters  
 Accuracy 
 Specificity  
 Sensitivity 
 Reproducibility 
ICH validation parameters: 
 Specificity  
 Linearity 
 Range  
 Accuracy 
 Precision 
o Repeatability 
o Intermediate Precision 
o Reproducibility 
 Limit of detection  
 Limit of quantification 
 Robustness 
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1.3.6 ICH characteristics and guidelines: 
Table:7 ICH characteristics and guidelines 
Analytical task Major 
qualitative 
analysis 
Minor 
quantitative 
analysis 
Minor 
qualitative 
analysis 
Major 
quantitative 
analysis 
Specificity Yes Yes Yes Yes 
Linearity No Yes No Yes 
Range No Yes No Yes 
Accuracy No No Yes Yes 
                 Precision 
 Repeatability 
 Intermediate Precision 
 Reproducibility 
 
No 
No 
No 
 
Yes 
Yes 
No 
 
No 
No 
No 
 
Yes 
Yes 
No 
Limit of detection No No Yes No 
Limit of quantification No Yes No No 
 
1.3.7 Validation of an analytical method: 
Method validation parameters as per ICH guidelines are summarized below. 
a) Specificity 
Specificity is the ability of the method to measure accurately and specifically the 
analyte of interest in the presence of matrix and other components likely to be present in the 
sample matrix and impurities, degradation products and other related substances. If the 
impurities/degradation products or potential contaminants are not available, one can 
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apply a proposed method for strained and stressed (heat, light, humidity) samples. Lack of 
specificity of an individual analytical procedure may be compensated by other supporting 
analytical procedure(s). 
Acceptance Criteria: There should not be any interference in the assay by the spiked 
impurity and 1 % of initial also the assay value obtained should be within assay. 
b) Linearity 
           The linearity of an analytical method is its ability (within a given range) to obtain test 
results, which are directly proportional to the concentration (amount) of analyte in the 
samples within a given range. 
 
Fig.1 definition of linearity 
c) Range 
        The range of an analytical method is the interval between the upper concentration and 
lower concentration of analyte with a suitable level of precision, accuracy and linearty. The 
ICH recommends that, for the establishment of linearity, a minimum of five concentrations 
normally be used.  
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d) Accuracy 
The accuracy of an analytical method relates the closeness of the test results to true 
value i.e. measure of exactness of analytical method. It is expressed as % recovery by the 
assay of known/added amount of analyte in the linearity range. One can design 
experiments for recovery of known or spiked samples (usually 10% of the claim) in 
presence of expected matrix, keeping the matrix constant. Accuracy can also be determined 
by comparing the results those obtained using an alternative method, which has been 
validated. 
e) Precision 
The precision of an analytical method express the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. The precision of an analytical 
method is usually expressed as the variance, standard deviation or coefficient of variance of 
a series of measurements. 
Precision may be considered at three levels, 
 Repeatability 
 Reproducibility  
 Intermediate precision 
Repeatability: (under same conditions): Precision of the method when repeated by the same 
analyst, same test method and under same set of laboratory conditions (reagent, equipments 
etc.) within a short interval of time, the only difference being the sample. The 
repeatability of any test Procedure is required to be assured by carrying out complete 
separate determination on separate sample of the same homogeneous batch of material under 
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normal laboratory conditions.  
Acceptance Criteria: The individual assay value should not vary by more than 2 %. Relative 
standard deviation should not be more than 2 %. 
Reproducibility: (under different conditions): Reproducibility expresses the precision when 
the subject method is carried out by different analysts in different laboratories, using 
different equipments, reagents and laboratory settings and on different days- variability of 
analytical results as function of analyst, day-to-day, laboratory–to-laboratory, equipment-to-
equipment etc. Using the samples from same homogeneous batch. 
Intermediate Precision: Intermediate precision expresses within the same laboratory 
variations but different days, different analysts, different equipment and reagents. 
f) Limit of Detection 
          Limit of detection of an individual analytical method is the lowest concentration / 
amount of analyte in a sample that the method can detect but not necessarily quantify under 
the stated experimental conditions. The LOD will not only depend on the procedure of 
analysis but also on the type of instrument. 
a) Instrumental  
 S / N = 3:1 
 2-3 times of SD of blank response. 
    b) Non-instrumental: One has to establish the minimum level at which analyte can be reliably 
detected usually LOD is 2-3 times lower than LOQ. 
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g) Limit of Quantification 
          Limit of quantification of an individual analytical method is the lowest concentration/ 
amount of analyte in a sample, which can be quantitatively determined with suitable 
precision and accuracy under stated experimental conditions. The quantification limit is used 
particularly for the determination of impurities and / or degradation products. The LOQ will 
not only depend on the procedure of analysis but also on the type of instrument. 
a) instrumental: 
 S/N = 10:1 
 3 times higher than LOD 
b) Non-instrumental: One has to establish the level experimentally depending on the method 
of analysis. 
Acceptance Criteria: The assay value obtained so should be within ± 2 % of initial assay 
value. 
h) Robustness 
         Robustness is the measure of the analytical method to remain unaffected by small, but 
deliberate variations in method parameters. It provides an indication of its reliability during 
normal usage. 
i) System Suitability 
        System Suitability is defined ability of the method produce constant response for the 
system parameters. If measurements are susceptible to variations in analytical conditions, a 
precautionary statement should be included in the method or these variations should be 
suitably controlled. Typical variations are the different equipment, different analysts and the 
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stability of analytical solutions. 
Acceptance criteria: The RSD variation of the results ± 2.5 %. 
System Suitability parameters and acceptance criteria for HPLC 
The accuracy and precision of HPLC data collected begin with a well behaved 
chromatographic system. The system suitability specifications and tests are parameters 
that provide assistance in achieving this purpose. 
 Capacity factor (k') 
The capacity factor is a measure of the degree of retention of an analyte relative to an 
unretained peak, where TR is the retention time for the sample peak and t0 is the retention 
time for an unretained peak. 
                                                          k' = (tR- t0 ) / t0 
Acceptance criteria: The peak should be well-resolved from other peaks and the void 
volume. Generally the value of k' is > 2. 
 2. Resolution (Rs) 
Ability of column to achieve baseline separation of chromatographic peaks. Resolution can 
be improved by increasing column length, decreasing particle size, increasing temperature, 
changing the eluent or stationary phase. It can also be expressed in terms of the separation 
of the apex of two peaks divided by the tangential width average of the peaks. 
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Fig.2 expression of resolution between two peaks 
                                               Rs = ΔtR / 0.5 (W1 + W2); 
                                          Where; ΔtR = t2 – t1 
For reliable quantitation, well-separated peaks are essential for quantitation. 
Acceptance criteria: Rs of > 2 between the peak of interest and the closest potential 
interfering peak (impurity, excipients, degradation product, internal standard, etc.) are 
desirable. 
 3. Tailing factor (T) 
A measure of the symmetry of a peak, given by the following equation where W0.05 is 
the peak width at 5% height and f is the distance from peak front to apex point at 5% height. 
Ideally, peaks should be Gaussian in shape or totally symmetrical. 
                                              T = W0.05 / 2f 
                                              T       = Tailing factor 
                                             W0.05 = Width of peak at 5% of height 
                                               f       = Width of the peak front at peak maximum 
The accuracy of quantitation decreases with  increase  in peak  tailing  because of 
the difficulties encountered by the integrator in determining where/when the peak ends and 
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hence the calculation of the area under the peak. Integrator variables are preset by the 
analyst for optimum calculation of the area for the peak of interest. 
Acceptance criteria: The tailing factor of peak should not more than 2. 
 4. Theoretical plate number / Efficiency (N) 
A measure of peak band spreading determined by various methods, some of which are 
sensitive to peak asymmetry. The most common are shown here, with the ones most 
sensitive to peak shape shown first: 4-sigma / tangential. 
                            N = 16 (tR / W)
2
  = L / H Half height 
                                    N = 5.54 (tR / W)
2 
= L / H 
Theoretical plate number is a measure of column efficiency, that is, how many peaks 
can be located per unit run-time of the chromatogram, where tR is the retention time for the 
sample peak and W is the peak width. N is fairly constant for each peak on a chromatogram 
with a fixed set of operating conditions. H, or HETP, the height equivalent of a theoretical 
plate, measures the column efficiency per unit length (L) of the column. Parameters which 
can affect N or H include Peak position, particle size in column, flow- rate of mobile phase, 
column temperature, viscosity of mobile phase, and molecular weight of the analyte.  
Table: 8 Acceptance criteria of validation parameters for HPLC 
S.No. 
Characteristics 
 
Acceptance criteria 
 
1 
Accuracy 
 
Recovery 98-102% 
2. Precision %RSD < 2 
3 
Specificity/Selectivity 
 
No interference 
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4 Detection limit 
S/N > 2 or 3 
 
5 
Quantitation limit 
 
S/N > 10 
 
6 
Linearity 
 
r2> 0.999 
 
7 
Range 
 
80 - 120% 
 
8 
Stability 
 
>24 h or < 8h 
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1.4 Forced degradation studies 
Forced degradation studies of drug substance and products play an integral role in the 
development of pharmaceuticals. The results of degradation studies facilitate stability 
indicating method (SIM) development, the design of formulations, the choice of storage 
conditions and packaging, an understanding of the chemistry of the drug molecule, and 
stability problem solving.  
1.4.1 Degradation pathways 
Forced degradation or stress studies of drug substances are usually conducted in solution and 
the solid state at temperatures exceeding accelerated stability conditions (>40°C) . The 
degradation pathways investigated include hydrolysis, oxidation, thermolysis, photolysis, and 
polymerization.  
Table: 9 degradation pathways 
S.no Pathways Mechanism 
1. hydrolysis exposure of drug to high relative humidity 
2. oxidation control of exposure to molecular oxygen or addition of 
oxidizing agent like peroxides 
3. thermolysis application of heat 
4. photolysis irradiating the drug with light at 300 – 800 wavelength 
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1.4.2 Condition for stress testing:  
Table: 10 recommended stress conditions for drug substances 
Stress type Conditions Time 
Acid hydrolysis 
Base hydrolysis 
Thermal hydrolysis 
Oxidative solution 
 
 
 
Thermal 
 
Thermal/Humidity 
0.1N HCl(up to 5.0 N) 
0.1N NaOH/KOH ( up to 5.0 N) 
70ºC 
O2+Initiator(AIBN) in 
Acetonitrile/H2O, 80/20;40ºC 
0.3% (up to 3%) H2O2;  
RT; protected from light 
70ºC 
70ºC/75%RH 
1-7 days 
1-7 days 
1-7 days 
 
1-7 days 
 
Few hrs to 7 days 
up to 2 weeks 
up to 2 weeks 
 
Table: 11 recommended stress conditions for drug product 
 
 
Stress type Conditions Time 
Thermal 
Thermal/humidity 
Photo-degradation 
70ºC 
70ºC/75%RH 
Fluorescent and 
UV light 
Up to 3 weeks 
Up to 3 weeks 
 
>2 weeks 
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1.4.3 Stability Guidelines  
ICH: International Conference on Harmonization of technical requirements for registration of 
pharmaceuticals for human use.  
WHO: World Health Organization. 
USFDA: United States food drug administration. 
GMP: Good manufacturing practices.  
The ICH Topics are divided into four major categories:  
 Quality (Q), i.e., those relating to chemical and pharmaceutical Quality Assurance  
 Safety (S), i.e., those relating to in vitro and in vivo preclinical studies  
 Efficacy (E), i.e., those relating to clinical studies in human subject  
 Multidisciplinary topics (M), i.e., cross-cutting Topics which do not fit uniquely into 
one of the above categories.  
1.4.4 Quality Guidelines – Stability, Validation & Impurities  
a) Stability Q1A - Q1F  
              Q1A (R2) - Stability Testing of New Drug Substances and Products Q1A  
Q1B- Stability Testing: Photo stability Testing of New Drug Substances and Products  
Q1C - Stability Testing for New Dosage Forms  
Q1D -Bracketing and Matrixing Designs for Stability Testing of New Drug Substances  
and products 
Q1E - Evaluation of Stability Data  
Q1F - Stability Data Package for Registration Applications in Climatic Zones   III & IV. 
b) Q2 (R1) Validation of Analytical Procedures: Text and Methodology 
c) Impurities Q3A - Q3D  
Q3A (R2) Impurities in New Drug Substances  
Q3B (R2) Impurities in New Drug Products  
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Q3C (R5) Impurities: Guideline for Residual SolventsQ3C, Q3C (M)  
Q3DImpurities: Guideline for Metal Impurities  
1.4.5 Stability Testing of New Drug Substances  
a) Testing Frequency: 
For long term studies, frequency of testing should be sufficient to establish the stability 
profile of the drug substance. For drug substances with a proposed re-test period of at least 12 
months, the frequency of testing at the long term storage condition should normally be every 
3 months over the first year, every 6 months over the second year, and annually thereafter 
through the proposed re-test period. At the accelerated storage condition, a minimum of three 
time points, including the initial and final time points (e.g., 0, 3, and 6 months), from a 6-
month study is recommended. Where an expectation (based on development experience) 
exists that results from accelerated studies are likely to approach significant change criteria, 
increased testing should be conducted either by adding samples at the final time point or by 
including a fourth time point in the study design.  
When testing at the intermediate storage condition is called for as a result of significant 
change at the accelerated storage condition, a minimum of four time points, including the 
initial and final time points (e.g., 0, 6, 9, 12 months), from a 12-month study is 
recommended. 
b) Storage Conditions: 
In general, a drug substance should be evaluated under storage conditions (with appropriate 
tolerances) that test its thermal stability and, if applicable, its sensitivity to moisture. The 
storage conditions and the lengths of studies chosen should be sufficient to cover storage, 
shipment, and subsequent use. The long term testing should cover a minimum of 12 months 
duration on at least three primary batches at the time of submission and should be continued 
for a period of time sufficient to cover the proposed re-test period. Additional data 
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accumulated during the assessment period of the registration application should be submitted 
to the authorities if requested. Data from the accelerated storage condition and if appropriate, 
from the intermediate storage condition can be used to evaluate the effect of short term 
excursions outside the label storage conditions (such as might occur during shipping). Long 
term, accelerated and where appropriate, intermediate storage conditions for drug substances 
are detailed in the sections below. The general case applies if the drug substance is not 
specifically covered by a subsequent section. Alternative storage conditions can be used if 
justified.      
i) General case 
Table: 12 Drug substances intended for storage at normal conditions 
*It is up to the applicant to decide whether long term stability studies are performed at 25 
2°C/60% RH 5% RH or 30°C 2°C/65% RH 5% RH. 
**If 30°C 2°C/65% RH 5% RH are the long-term condition, there is no intermediate 
condition. 
If long-term studies are conducted at 25°C ± 2°C/60% RH ± 5% RH and “significant change” 
occurs at any time during 6 months testing at the accelerated storage condition, additional 
testing at the intermediate storage condition should be conducted and evaluated against 
significant change criteria. Testing at the intermediate storage condition should include all 
Study Storage condition Minimum time period 
covered by data at 
submission 
 
 
Long term* 
25°C ± 2°C/60% RH ± 5% RH or  
30°C ± 2°C/65% RH ± 5% RH 
 
12 months 
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tests, unless otherwise justified. The initial application should include a minimum of 6 
months’ data from a 12-month study at the intermediate storage condition. “Significant 
change” for a drug substance is defined as failure to meet its specification. 
ii) Drug substances intended for storage in a refrigerator. 
Table: 13 Drug substances intended for storage in a refrigerator 
Data from refrigerated storage should be assessed according to the evaluation section of this 
guideline, except where explicitly noted below. If significant change occurs between 3 and 6 
months testing at the accelerated storage condition, the proposed re-test period should be 
based on the real time data available at the long term storage condition.  
If significant change occurs within the first 3 months testing at the accelerated storage 
condition, a discussion should be provided to address the effect of short term excursions 
outside the label storage condition, e.g., during shipping or handling. This discussion can be 
supported, if appropriate, by further testing on a single batch of the drug substance for a 
period shorter than 3 months but with more frequent testing than usual. It is considered 
unnecessary to continue to test a drug substance through 6 months when a significant change 
has occurred within the first 3 months.  
 
 
 
 
 
Study Storage condition Minimum time period covered by 
data at submission 
Long term 5°C ± 3°C 12 months 
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iii) Drug substances intended for storage in a freezer 
Table: 14 Drug substances intended for storage in a freezer 
For drug substances intended for storage in a freezer, the re-test period should be based on 
the real time data obtained at the long term storage condition. In the absence of an accelerated 
storage condition for drug substances intended to be stored in a freezer, testing on a single 
batch at an elevated temperature (e.g., 5°C ± 3°C or 25°C ± 2°C) for an appropriate time 
period should be conducted to address the effect of short term excursions outside the 
proposed label storage condition, e.g., during shipping or handling.  
iv) Drug substances intended for storage below -20°C  
Drug substances intended for storage below -20°C should be treated on a case-by-case basis.  
1.4.6 Stability Testing of Drug Product: 
a) Testing Frequency: 
For long term studies, frequency of testing should be sufficient to establish the stability 
profile of the drug product. For products with a proposed shelf life of at least 12 months, the 
frequency of testing at the long term storage condition should normally be every 3 months 
over the first year, every 6 months over the second year, and annually thereafter through the 
proposed shelf life. At the accelerated storage condition, a minimum of three time points, 
including the initial and final time points (e.g., 0, 3, and 6 months), from a 6-month study is 
recommended. Where an expectation (based on development experience) exists that results 
from accelerated testing are likely to approach significant change criteria, increased testing 
should be conducted either by adding samples at the final time point or by including a fourth 
Study Storage condition Minimum time period covered by 
data at submission 
Long term - 20°C ± 5°C 12 months 
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time point in the study design. When testing at the intermediate storage condition is called for 
as a result of significant change at the accelerated storage condition, a minimum of four time 
points, including the initial and final time points (e.g., 0, 6, 9, 12 months), from a 12-month 
study is recommended. Reduced designs, i.e., matrixing or bracketing, where the testing 
frequency is reduced or certain factor combinations are not tested at all, can be applied, if 
justified.  
b) Storage Conditions: 
In general, a drug product should be evaluated under storage conditions (with appropriate 
tolerances) that test its thermal stability and, if applicable, its sensitivity to moisture or 
potential for solvent loss. The storage conditions and the lengths of studies chosen should be 
sufficient to cover storage, shipment, and subsequent use. Stability testing of the drug product 
after constitution or dilution, if applicable, should be conducted to provide information for 
the labeling on the preparation, storage condition, and in-use period of the constituted or 
diluted product. This testing should be performed on the constituted or diluted product 
through the proposed in-use period on primary batches as part of the formal stability studies 
at initial and final time points and, if full shelf life long term data will not be available before 
submission, at 12 months or the last time point for which data will be available. In general, 
this testing need not be repeated on commitment batches. The long term testing should cover 
a minimum of 12 months’ duration on at least three primary batches at the time of submission 
and should be continued for a period of time sufficient to cover the proposed shelf life. 
Additional data accumulated during the assessment period of the registration application 
should be submitted to the authorities if requested. Data from the accelerated storage 
condition and, if appropriate, from the intermediate storage condition can be used to evaluate 
the effect of short term excursions outside the label storage conditions (such as might occur 
during shipping). Long term, accelerated, and, where appropriate, intermediate storage 
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conditions for drug products are detailed in the sections below. The general case applies if the 
drug product is not specifically covered by a subsequent section. Alternative storage 
conditions can be used, if justified. 
i) General case  
Table: 15 Drug products intended for storage at normal conditions 
*It is up to the applicant to decide whether long term stability studies are performed at 25 
2°C/60% RH 5% RH or 30°C 2°C/65% RH 5% RH.  
**If 30°C 2°C/65% RH 5% RH is the long-term condition, there is no intermediate condition. 
If long-term studies are conducted at 25°C ± 2°C/60% RH ± 5% RH and “significant change” 
occurs at any time during 6 months testing at the accelerated storage condition, additional 
testing at the intermediate storage condition should be conducted and evaluated against 
significant change criteria. The initial application should include a minimum of 6 months data 
Study Storage condition Minimum time period 
covered by data at 
submission 
 
Long term* 
25°C ± 2°C/60% RH ± 5% RH 
or 
30°C ± 2°C/65% RH ± 5% RH 
 
12 months 
Intermediate** 30°C ± 2°C/65% RH ± 5% RH               6 months 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months 
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from a 12-month study at the intermediate storage condition. In general, significant change 
for a drug product is defined as:  
A 5% change in assay from its initial value or failure to meet the acceptance criteria for 
potency when using biological or immunological procedures, any degradation product’s 
exceeding its acceptance criterion.  
Failure to meet the acceptance criteria for Appearance  
Physical attributes: (e.g., softening of suppositories, melting of creams) may be expected    
                                under accelerated conditions. 
Functionality test:  (e.g., color, phase separation, re suspendability, caking, hardness, dose   
                               delivery per actuation) 
Failure to meet the acceptance criterion for pH 
Failure to meet the acceptance criteria for dissolution for12 dosage units.  
iv) Drug products intended for storage in a refrigerator  
Table: 16 Drug products intended for storage in a refrigerator 
If significant change occurs within the first 3 months testing at the accelerated storage 
condition, a discussion should be provided to address the effect of short term excursions 
outside the label storage condition, e.g., during shipment and handling. This discussion can 
be supported, if appropriate, by further testing on a single batch of the drug product for a 
Study Storage condition Minimum time period 
covered by data at 
submission 
Long term 5°C ± 3°C 12 months 
Accelerated 25°C ± 2°C/60% RH ± 5% RH 6 months 
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period shorter than 3 months but with more frequent testing than usual. It is considered 
unnecessary to continue to test a product through 6 months when a significant change has 
occurred within the first 3 months. 
Table: 17 Drug products intended for storage in a freezer 
For drug products intended for storage in a freezer, the shelf life should be based on the real 
time data obtained at the long term storage condition. In the absence of an accelerated storage 
condition for drug products intended to be stored in a freezer, testing on a single batch at an 
elevated temperature (e.g.,5°C ± 3°C or 25°C ± 2°C) for an appropriate time period should be 
conducted to address the effect of short term excursions outside the proposed label storage 
condition. 
                           
 
 
 
 
 
 
  
Study Storage condition Minimum time period covered by 
data at submission 
Long term - 20°C ± 5°C 12 months 
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2. LITERATURE REVIEW 
2.1 Drug profile of Eletriptan hydrobromide: 
Non pharmacopoeial drug  
Description                       :           white to light pale colored powder 
Structure                           : 
                                                     
                                                      Fig.3 structure of Eletriptan hydrobromide 
IUPAC name                    :           (R)-3-[(-1-Methyl-2-pyrrolidin-2-yl)methyl]-5-[2- 
                                                     (phenylsulfonyl)ethyl]-1H-indole, monohydrobromide  
Molecular weight             :           463.40 
Solubility                          :           soluble in water and acetonitrile,  
                                                      methanol and DMSO                                       
Melting range                   :           169- 171ºC 
Stability                            :            Very stable molecule under normal conditions. 
Wavelength (λ max)           :            225nm 
Category                          :             Anti-migraine drug 
Mechanism of action       :             Seratonin receptor agonist 
Brand name                     :             Relpax, Relert. 
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Pharmacokinetic Data         
Bioavailability                 :             50% 
Protein Binding               :             85% 
Metabolism                      :             N-demethylation. Cytochrome P450 CYP3A4,  
Half Life                           :            13 hrs 
Excretion                          :            >90% via faeces, 9% urine 
Dosage form                     :            Tablets 
Dose                                  :            20 mg, 40 mg.  
Table: 18 List of marketed formulations of Eletriptan hydrobromide tablets: 
S.no Brand Name Dose dosage form Manufacturing Company 
1. Relert 40mg Tablet Pfizer Pharmaceuticals  Ltd. 
2. Relpax 40mg Tablet Pfizer Pharmaceuticals  Ltd. 
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2.2 Literature Review of Eletriptan hydrobromide  
Table: 19 previously developed analytical methods on Eletriptan hydrobromide: 
S.no Title Column Mobile Phase Linearity ref. 
no 
1. 
 
 
Development and 
validation of RP-HPLC 
method for estimation of 
Eletriptan hydrobromide 
in bulk & 
pharmaceutical 
formulation. 
Phenomenax 
Lunac C18 
(250mmx4.6
mmx5µm) 
KH2PO4 Buffer: 
Acetonitrile 
(60:40)v/v 
5-30µg/ml 
of Ele 
HBr 
14 
2. 
 
 
RP-HPLC method for 
estimation of Eletriptan 
hydrobromide in bulk & 
pharmaceutical 
formulation. 
Inertsil ODS- 
C18 
(250mmx4.6
mmx5µm) 
0.01 M KH2PO4     
Buffer:ACN : 
methanol(20:40:40)
v/v/v 
200-1000 
µg/ml of 
Ele HBr 
13 
3. 
 
 
Validation of HPLC 
method for simultaneous 
determination of 
Eletriptan hydrobromide 
and UK 120.413 
X-terra, 
C18(150mm
x4.6mmx5.0
µm) 
TEA :Methanol 
(67.2:32.8)v/v 
0.05-1.00 
mg/ml of 
Ele HBr 
16 
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4. 
 
Method development 
and estimation of 
eletriptan hydrobromide 
in pharmaceutical 
dosage form by RP-
HPLC 
Inertsil ODS-
3 V C18 
(250mmx4.6
mmx5µm) 
0.03 M Ammonium 
acetate buffer, TEA 
(0.5%):Methanol 
(40:60)v/v 
 
50-600 
µg/ml of 
Ele HBr 
22 
5. An Isocratic RP-HPLC 
Method development for 
determination of 
Eletriptan hydrobromide 
in bulk & 
pharmaceutical dosage 
form. 
Zorbax 
SB,C18 
(150mmx4.6
mmx5µm) 
 
 Ammonium 
acetate,Buffer:ACN 
(80:20)v/v 
20-70 
µg/ml of 
Ele HBr 
19 
6. Development and 
validation of stability 
indicating  RP-HPLC 
method for 
determination of 
Eletriptan hydrobromide 
in orally disintegrated 
tablets 
Thermo 
column, C18 
(150mmx4.6
mmx5µm) 
Methanol;Water 
(35:65) v/v 
5-500 
µg/ml of 
Ele HBr 
18 
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7. Method development 
and validation for 
determination of 
Eletriptan hydrobromide 
in bulk & 
pharmaceutical dosage 
form by RP-HPLC 
Waters 
symmetry 
column,C18 
(100mmx4.6
mmx3.5µm) 
KH2PO4,Buffer: 
ACN(60:40)v/v 
10-50 
µg/ml of 
Ele HBr 
26 
8. Development and 
validation of a stability 
indicating RP-HPLC 
method for 
determination of 
Eletriptan hydrobromide 
in pharmaceutical 
formulation. 
Phenomenex 
Chromosil 
C18,(250mm
x4.6mmx 
5µm) 
Acetonitrile :TEA 
:THF (50:25:25) 
v/v/v 
30-100 
µg/ml of 
Ele HBr 
27 
9. Method development 
and validation of 
eletriptan hydrobromide 
by UV-Visible 
spectrophotometry. 
- 
Ethanol and 
distilled water 
1-10µg/ml 
of Ele 
HBr 
20 
39 
 
10. Liquid chromatographic 
determination of 
Eletriptan in 
pharmaceutical dosage 
forms 
Nova-pak 
C18(250mm
x4.6mmx5µ
m) 
ACN : 
Water(60:40) 
100-4500 
µg/ml of  
Ele HBr 
17 
11. Development and 
application of an HPLC 
method for Eletriptan 
hydrobromide 
Shim-pak VP 
ODS 
C18(250mm
x4.6mmx5µ
m) 
KH2PO4,P
H 5.0 
with OPA 
Buffer:Methanol:A
CN(40:15:45) 
320-20000 
µg/ml of 
Ele HBr 
26 
12. New Derivative 
Spectrophotometric 
Methods for 
Determination of 
Eletriptan 
hydrobromide. 
 
- 
A- 0.1N HCL 
B- Acetate buffer 
C- phosphate buffer 
0.5-0.3 
0.5-0.3 
1-30 
µg/ml of 
Ele HBr 
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3. AIM AND PLAN OF WORK 
The drug analysis plays an essential role in the development of drugs, their manufacture and 
the therapeutic use. Pharmaceutical industries rely upon quantitative chemical analysis to 
ensure that the raw materials used and final product obtained meets the required specification. 
The number of drug formulations and drugs introduced in to the market has been increasing 
at an alarming rate. These drugs or formulations may be either in the new entities in the 
market or novel dosage forms or multi component dosage forms or partial structural 
modification of the existing drugs. For the present study Eletriptan Hydrobromide drug was 
selected. Eletriptan Hydrobromide is chemically known as Hydrochloride (R)-3-[(-1-Methyl-
2-pyrrolidin-2-yl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole,monohydrobromide. It act 
as an anti Migraine drug. 
Objective:  
Literature reveals that, various methods like HPLC, UPLC, HPTLC, RP-HPLC 
methods has been develop for the estimation of Eletriptan Hydrobromide alone and along 
with various dosage forms. Few stability indicating RP-HPLC methods were reported for 
estimation of Eletriptan Hydrobromide. But stability indicating assay method for 
determination of Eletriptan Hydrobromide was not available. So, the main objective of work 
is, to develop new stability indicating assay method for determination of drug Eletriptan 
Hydrobromide by using RP-HPLC. 
Specific aim:  
To achieve the above objective the study was carried out in following steps: 
 To develop a simple, selective, sensitive, specific, precise stability indicating assay method 
by using reverse phase liquid chromatography.  
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 To validate the method in accordance with ICH guidance lines for the intended analytical 
application. The validation parameters as per ICH include specificity, system suitability, 
linearity, accuracy, precision, range, robustness.  
 To perform stress degradation studies for Eletriptan Hydrobromide tablets. 
 To apply the developed and validated method for the quantitative analysis of Eletriptan 
Hydrobromide tablets. 
Plan of work: 
 Selection of API 
 Literature survey 
 Method development 
 Optimization of LC conditions 
 Validation of developed method as per ICH guidelines  
 Perform degradation studies of Eletriptan Hydrobromide  
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4. EXPERIMENTAL WORK 
4.1 List of materials 
Table: 20 Apparatus/Instruments used 
S. No Apparatus Model Make 
1. HPLC LC-2010+ Shimadzu 
2. Semi micro balance CPA2P Sartorius 
3. Sonicator UCB 70 Spectralab 
4. Glassware Borosilicate type-A* - 
5. Membrane Filters 0.45 and 0.2µm PALL life sciences 
*calibrated as per Indian Pharmacopoeia 2007 
Table: 21 Chemicals/Reagents used 
S. No Chemicals Grade Manufacturer 
1. Potassium dihydrogen 
ortho phosphate  
ACS Merck 
2. Ortho phosphoric acid  ACS Merck 
3. Sodium hydroxide  ACS Merck 
4. Hydrochloric acid ACS Merck 
43 
 
5. Hydrogen peroxide GR Merck 
6. Acetonitrile HPLC Merck 
8. Methanol  HPLC Merck 
9. Purified water Milli-Q Finoso pharma pvt Ltd. Hyd. 
Table: 22 Reference standard, Sample used 
1. Reference standard Eletriptan HBr 
2. Sample Eletriptan HBr 20mg and 40mg 
 
4.2 Instrumentation 
Table: 23 Description of LC instrument used 
1. HPLC Shimadzu 2010+ 
2. Software LC Solutions 
3. Column Waters X-terra, RP18, 250 x 4.6 mm, 5µ  
4. Pump Gradient 
4. Detector UV-PDA 
5. Injection System Rheodyne Injector 
6. Injection Volume 5µl 
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4.3 Method development by RP-HPLC  
4.3.1 Selection of Detector Wavelength: 
Appropriate dilution was prepared from stock solution of Ele HBr, the solution were scanned 
over the range of 200- 400nm. 225nm has been selected as a detection wavelength for HPLC 
method.  
4.3.2 Preparation of mobile phase 
Preparation of mobile phase A: 
Prepare a degassed mixture of Phosphate buffer pH 7.0 and Acetonitrile in the ratio 98:2 v/v. 
Preparation of mobile phase B: 
Prepare a degassed mixture of Acetonitrile and Methanol in the ratio 80:20 v/v. 
4.3.3 Preparation of diluting solvent: 
Prepare a degassed mixture of Phosphate buffer pH 7.0 & Acetonitrile in the ratio 55:45 v/v.  
4.3.4 Preparation of standard drug solution: 
60.57mg of Ele.HBr working standard was weighed and transferred in to 100ml V.F. 
 
To above solution 50ml of diluent was added and subjected to sonication for 2minutes. 
 
The volume was made up to the mark with diluting solvent. 
 
From the above solution 5ml was transferred in to 50ml V.F. 
 
The volume was made up to the mark with diluting solvent. 
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4.3.5 Optimization of mobile phase ratio and chromatographic conditions: 
To optimize the chromatographic conditions different trails were performed by injecting the 
standard solution of Erl.HCL on Waters X-terra column at different ratios of mobilephase. 
The results of trails are shown in table no. 24 
4.3.6 Optimized Chromatographic conditions: 
Mobile phase A (55%) consisted of Phosphate buffer pH 7.0 and Acetonitrile in the ratio 98:2 
v/v. 
Mobile phase B (45%) consisted of Acetonitrile and Methanol in the ratio 80:20 v/v. 
The column temperature was 25ºC.  
The eluent was monitored at 225nm. 
The optimized Chromatographic conditions were shown in table no. 25 
4.3.7 Calibration of standards: 
Standard calibration line for the Ele.HBr was constructed by transferring different volumes of 
standard stock solution in to appropriate V.F and diluted up to the mark with diluting solvent 
to yield concentration range of 10-150 μg/ml of Ele.HBr. The calibration line was obtained 
by plotting peak area ratio against the concentration of drug. 
4.4 Validation of developed method (RP-HPLC) 
The developed method was validated as per ICH guidelines. Method validation was 
performed in terms of System suitability, Linearity and Range, Assay, Accuracy, Precision, 
Specificity and selectivity, Robustness. 
4.4.1. System suitability: 
It is defined as ability of the method produce constant response for the system parameters. 
System suitability was performed to verify the analytical system working properly and can 
produce accurate and precise results. The system suitability was carried out after the method 
development and validation have been completed. For this, parameters like plate number (N), 
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resolution (Rs), tailing factor, capacity factor, HETP, peak symmetry of samples were 
measured. The represented data was shown in table no.26 
 4.4.2. Linearity and Range: 
Linearity defined as, ability of the method elict the test results which are directly proportional 
to test concentrations. The linearity of the calibration curves in pure solution of Ele.HBr was 
checked over the concentration range of 10-150 μg/ml of Ele.HBr. The total eluting time was 
less than 10 mins by using regression analysis, the regression line of standard concentrations 
of Ele.HBr was founded. The calibration curves were linear in the entire studied range and 
the equation of regression analysis was obtained. 
Y= 29,193.2694x – 16,433.0727; R² = 0.9999 for Ele.HBr. 
The mean ± standard deviation (SD) for the slope, correlation coefficient, and intercept of the 
standard curves (n=3) were calculated. The represented data was shown in table no.27 & 28 
4.4.3. Assay: 
This parameter was performed to determine the purity of the dosage form in order to see 
whether the method is applicable for the formulation analysis or not. Weigh and finely 
powdered not fewer than 20 tablets. A powder quantity equivalent to 50mg of Ele.HBr was 
transferred in to 100ml V.F, to this 50ml of diluting solvent was added, and subjected to  
sonication for 10minutes along with intermediate shaking and volume was made up to the 
mark with diluting solvent. The above solution was filtered through 0.45µ nylon membrane 
syringe. From this solution 5ml was transferred in to 50ml V.F and made up to the mark with 
diluting solvent. Injected under optimized chromatographic conditions and peak area was 
measured. The assay procedure was made triplicate and weight of the sample taken for assay 
was calculated. The percentage of drug found in formulation, standard deviation and mean 
was calculated. The results were shown in table no. 29 
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4.4.4 Accuracy: 
Accuracy was determined by performing recovery studies at three levels in which, known 
amount of reference standard of the Ele.HBr at levels of 50%, 100% and 150% were added to 
the formulation. Recovery studies were carried out in three replicates of each concentration 
level and percentage recovery and percentage relative standard deviation of Ele.HBr were 
calculated and shown in table no.30 
4.4.5. Precision: 
a) Repeatability (Method precision): 
Repeatability is defined as, the ability of the analytical instrument to produce reproducible 
results. The system precision was studied by six replicate measurements standard solution of 
Ele.HBr, the results were shown in table no. 31 
b) Intermediate Precision:  
Intermediate precision expresses within the same laboratory but variations different days, 
different analysts, different equipment and reagents were used. Intraday and Inter day 
precision studies are performed, the results were shown in table no.32 & 33. 
4.4.6. Specificity and selectivity: 
The specificity of method was evaluated with regard to interference due to presence of any 
other excipients. (or) Specificity of the method was shown by quantifying the analyte of 
interest in the presence of matrix and other components, like Mobile phase, placebo and 
diluent. Volume of 5 µl of placebo, diluent, mobile phase were injected separately, the 
chromatogram was recorded and Those components have shown no peaks at retention time of 
5.09min, the proposed method was specific for the detection of Ele.HBr peak. The selectivity 
of the method was performed by injecting the impurities stock solution the impurities were 
well separated from the analyte peak. 
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4.4.7. Robustness: 
The capacity of the method remains unaffected by small but deliberate variations like mobile 
phase, PH, flow rate, wavelength. To evaluate Robustness, solution stability, filtration test and 
changes in chromatographic conditions, like variations in flow rate (± 0.2%) and wavelength 
(± 2%), column temperature were performed. (±5ºC)., organic phase ratio in M.P (± 10%), 
buffer PH (± 0.2%), 
a) Changes in chromatographic conditions: 
 Change in flow rate using flow rate 0.9ml and 1.1ml, instead of 1.0ml.  
 Change in wavelength, using 223nm and 227nm instead of 225nm. 
 Change in column temperature, 20ºC and 30ºC instead of 25ºC. 
 Change in organic phase ratio in mobile phase, +10% and -10% 
 Change in buffer PH to 6.8 and 7.2 instead of 7.0 
None of alterations caused any significant changes in peak area RSD, tailing factor and 
theoretical plates. Results were shown in table no.34 
b) Filtration test: 
One portion of 100% sample solution in accuracy study was centrifuged and another portion 
of sample solution was filtered through 0.45 GHP filter and PVDF filter. The results were 
compared. Results were shown in table no.35 
c) Solution stability test: 
A 100% sample and standard solutions were prepared and stored in clear vials at room 
temperature. Those solutions were re-quantified at 4hrs, 12hrs, 24hrs, and 48hrs. The 
recoveries of standard and sample solution were determined against freshly prepared standard 
preparation. 
Results were shown in table no.36 
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4.5 Stress degradation studies of Eletriptan Hydrobromide 
Stress degradation studies were performed as per ICH guidelines. Stress degradation is 
defined as degradation of new drug product or drug substance at conditions more severe than 
accelerated conditions. Which in turn help in the structural elucidation of degradation 
products of drug and also it is required to establish the specificity of stability indicating assay 
methods. In order to demonstrate the selectivity of the proposed method, stress degradation 
studies carried out by using acidic, alkali, thermal, uv-light, oxidative conditions. 
4.5.1 Procedure for stress degradation studies: 
To determine whether the analytical method and assay are stability indicating or not Ele.HBr 
was stressed under different conditions. like, acidic, alkali, thermal, uv-light, oxidative 
conditions to conduct forced degradation studies. Degradation was attempted to stress 
conditions of acidic (5N HCL), alkali (5N KOH), thermal (at 105ºC), oxidative (1% H2O2), 
uv-light (In UV- cabinet at 254 nm) to evaluate the ability of proposed method to estimate the 
content of Ele.HBr without interference of impurities and degradants formed due to FDS. 
If optimum degradation is observed under above conditions the process can be stopped at this 
point. If degradation is not observed under above conditions the drug should subjected to 
higher strengths and for longer time period. If complete degradation of drug achieved after 
subjecting the drug at initial conditions, the strengths of acidic, alkali, oxidative were 
decreased along with decrease in the reaction temperature. 
a) Preparation of diluting solvent: 
Mobile phase-A and Mobile phase-B in the ratio of 55:45 used as diluting solvent.  
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b) Preparation of Ele.HBr stock solution: 
60.45 mg Ele.HBr API was weighed and transferred in to 100ml V.F 
 
To above solution 50ml of diluent was added and subjected to sonication for 2min, the 
volume was made up to the mark with diluting solvent. 
(Ice water is used for process of sonication) 
 
Further 5 ml of above solution was transferred in to 50ml V.F and the volume was made up 
to the mark with diluting solvent. 
c) Preparation of 5N HCL: 
425 ml of concentrated HCL in 1000 ml of water. 
d) Preparation of 2N KOH: 
280 g of potassium di hydroxide in 1000 ml of water. 
4.5.2 Stress degradation studies: 
a) Acid degradation: 
Weigh and crush 20 tablets of Eletriptan with mortar pestle. 
 
 
Weigh and transfer an accurately weighed portion of the powder, equivalent to about 50 mg 
into 100 mL volumetric flask, 
 
 
Add 30 mL of diluent and sonicate for about 20 minutes, 
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To this add about 20 mL of 5N HCl and heat the sample at 60C for about 1 hour in water 
bath and cool to room temperature 
 
 
Neutralize with 20 mL of 5N Sodium Hydroxide, and make up to the volume with diluents, 
 
 
Filter through 0.45µm nylon filter. Transfer 5 mL of above solution into 50 mL of  
                volumetric flask, make up to volume with diluent and mix well.  
 
 
Above solution was injected under above chromatographic conditions and peak area was 
measured. 
 
b) Base degradation: 
Weigh and crush 20 tablets of Eletriptan with mortar pestle. 
 
 
Weigh and transfer an accurately weighed portion of the powder, equivalent to about 50 mg 
into 100 mL volumetric flask, 
 
 
Add 30 mL of diluent and sonicate for about 20 minutes, 
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To this add about 20 mL of 5N NaOH and heat the sample at 60C for about 1 hour in water 
bath and cool to room temperature 
 
 
Neutralize with 20 mL of 5N HCL, and make up to the volume with diluents, 
 
 
Filter through 0.45µm nylon filter. Transfer 5 mL of above solution into 50 mL of  
                volumetric flask, make up to volume with diluent and mix well.  
 
 
Above solution was injected under above chromatographic conditions and peak area was 
measured. 
 
c) Oxidative degradation: 
Weigh and crush 20 tablets of Eletriptan with mortar pestle. 
    
 
Weigh and transfer an accurately weighed portion of the powder, equivalent to about 50 mg 
into 100 mL volumetric flask, 
 
 
Add 30 mL of diluent and sonicate for about 20 minutes, 
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To this add about 20 mL of 1% Hydrogen peroxide and heat the sample at 60C for about 1 
hour  in water bath and cool to room temperature 
 
Neutralize with 20 mL of water, and make up to the volume with diluents, 
 
 
Filter through 0.45µm nylon filter. Transfer 5 mL of above solution into 50 mL of  
                volumetric flask, make up to volume with diluent and mix well.  
 
 
Above solution was injected under above chromatographic conditions and peak area was 
measured. 
 
d) Thermal degradation: 
Weigh and crush 20 tablets of Eletriptan with mortar pestle. 
    
 
Weigh and transfer an accurately weighed portion of the powder, equivalent to about 50 mg 
into 100 mL volumetric flask, 
 
 
Add 70 mL of diluent and sonicate for about 20 minutes, make up the volume with diluent. 
 
 
This V.F was placed in oven at temperature at 105ºC for 3 days. 
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Remove the flask, cooled it to room temperature. Filter through 0.45µm nylon filter.  
 
 
Transfer 5 mL of above solution into 50 mL of  volumetric flask, make up to volume with 
diluent and mix well.  
 
 
Above solution was injected under above chromatographic conditions and peak area was 
measured. 
e) UV-light degradation: 
Weigh and crush 20 tablets of Eletriptan with mortar pestle. 
    
 
Weigh and transfer an accurately weighed portion of the powder, equivalent to about 50 mg 
into 100 mL volumetric flask, 
 
 
Add 70 mL of diluent and sonicate for about 20 minutes, make up the volume with diluent. 
 
 
This V.F was placed in UV-cabinet  at 254 nm for 3 days. 
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Transfer 5 mL of above solution into 50 mL of volumetric flask, make up to volume with 
diluent and mix well.  
 
 
Above solution was injected under above chromatographic conditions and peak area was 
measured. 
The represented data of stress degradation study was shown in table no 37 
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5. RESULTS AND DISCUSSIONS 
 
5.1 Results for method development of RP-HPLC method for the determination of 
Eletriptan Hydrobromide tablets 
Table: 24 optimization of method for the determination of Eletriptan hydrobromide. 
i)Trial-1 
S.NO Parameter Optimized Conditions 
1. Column terra RP-18, 250x4.6mm,5µ 
2. Flow rate 1.0 ml/minute 
3. Column temperature 30°C 
4. wavelength 225 nm 
5. Injection volume  10 µl 
6. Runtime 6 minutes 
7. Mobile phase ratio M.P A 55: M.P B 45 
8. Retention time of drug 2.99 min 
 
Discussion: 
 The Eletriptan peak was eluted at 2.994 minutes  
 The theoretical Plates: 5258 and tailing factor: 1.35. 
 With this method the assay value is 95.1%  
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 In dissolution the average value is 100% result, but by observing the assay, 100 % result was 
not obtained, so this must be the extraction problem. Hence the diluent which is used must be 
changed (or) modified.  
ii)Trial-2 
S.NO Parameter Optimized Conditions 
1. Column terra RP-18, 250x4.6mm,5µ 
2. Flow rate 1.0 ml/minute 
3. Column temperature 30°C 
4. Wavelength 225 nm 
5. Injection volume  5 µl 
6. Runtime 6 minutes 
7. Mobile phase ratio M.P A 55: M.P B 45 
8. Retention time of drug 3.00 min 
 
Discussion: 
 The Eletriptan peak was eluted at 3.0 minutes  
 The theoretical Plates: 5278 and tailing factor : 1.34. 
 With this method the assay value is 97.1% . 
 With 10 minutes sonication time the assay value is 94.6. Hence for the sample more 
sonication required. 
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 With 20 minutes sonication time and 30 minutes sonication time the assay result is   are 97.1 
and 97.0 respectively. Hence sonication time for sample is 20 minutes. 
 By using the mobile phase as diluent,extraction of Eletriptan from Eletriptan hydrobromide 
tablets is improved. 
 There is no blank interference at the retention time of Eletriptan peak. 
iii)Trial-3 
S.NO Parameter Optimized Conditions 
1. Column terra RP-18, 250x4.6mm,5µ 
2. Flow rate 1.0 ml/minute 
3. Column temperature 25°C 
4. Wavelength 225 nm 
5. Injection volume  5 µl 
6. Runtime 10 minutes 
7. Mobile phase ratio M.P A 55: M.P B 45 
8. Retention time of drug 4.76 min 
 
Discussion: 
 The Eletriptan peak was eluted at 4.762 minutes  
 The theoretical Plates is8765 and tailing factor was 1.14. 
 With this method the assay value is 98.4%. 
 There is no blank interference at the retention time of Eletriptan peak. 
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iv)Trial-4 
S.NO Parameter Optimized Conditions 
1. Column X-terra RP-18, 250x4.6mm,5µ 
2. Flow rate 1.0 ml/minute 
3. Column temperature 25°C 
4. Wavelength 225 nm 
5. Injection volume  5 µl 
6. Runtime 10 minutes 
7. Mobile phase ratio M.P A 55: M.P B 45 
8. Retention time of drug 4.76 min 
 
Discussion: 
 With 5, 10, 15 &20 minutes sonication time the assay results are99.9%, 100.2%, 100.5% and 
100.7 % respectively.  
 With this method the assay value is 100.7%. Hence sonication time for sample is 20 minutes. 
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v)Trial-5 
S.NO Parameter Optimized Conditions 
1. Column terra RP-18, 250x4.6mm,5µ 
2. Flow rate 1.0 ml/minute 
3. Column temperature 25°C 
4. Wavelength 225 nm 
5. Injection volume  5 µl 
6. Runtime 10 minutes 
7. Mobile phase ratio M.P A 55: M.P B 45 
8. Retention time of drug 4.67 min 
 
Discussion: 
 The Eletriptan peak was eluted at 4.673 minutes and bromide peak was separated. 
 The theoretical Plates is3217 and tailing factor was 1.225. 
 With this method the assay value for centrifuged sample is 101.9% and with GHP filter is 
100.8%. 
 There is no much assay difference between centrifuged sample and GHP filtered sample  
 Hence GHP filters are suitable for sample filtration 
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5.1.1 Optimized chromatographic conditions  
Table: 25 Optimized chromatographic conditions of Eletriptan hydrobromide on C18 column. 
 
S.NO Parameter Optimized Conditions 
1. Column Waters X-terra, RP18, 250 x 4.6 mm,5µ 
2. Flow rate 1.0ml / min 
3. Column temperature 25˚C 
4. Injection volume 5µl 
5. Runtime 10 min 
6. Wavelength 225 nm 
7. Mobile phase ratio M.P A 55: M.P B 45 
8. Retention time of drug 5.09 min 
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5.1.2 Final optimized trail chromatograms during development process of method  
Assay Diluent: 
 
Assay Standard:   
 
Assay Sample:   
 
               Fig.4 Final optimized chromatograms 
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5.2 Results for validation of analytical method for the assay of Eletriptan 
Hydrobromide 
5.2.1 System Suitability  
Table: 26 System Suitability parameters for Eletriptan Hydrobromide. 
S.No Parameter Values obtained Limit 
1. Retention time  5.09 <5 min 
2. Peak area  1485452 - 
3. %RSD 0.28% <2% 
4. Tailing factor 1.52 <2% 
 
5.2.2 Linearity and Range  
              Table: 27 Calibration of Eletriptan Hydrobromide 
S.No  Target conc 
linearity levels  
Vol. of 
linearity 
stock 
solution(ml)  
Final 
dilution(ml)  
   Conc  
(µg/ml)  
    Area 
response  
1. Level 1 (25%) 1.3 50 13.119 374055 
2. Level 2 (50%) 2.5 50 25.229 716036 
3. Level 3 (80%) 4.0 50 40.367 1155081 
4. Level 4 (90%) 4.5 50 45.413 1308941 
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5. Level 5 (100%) 5.0 50 50.459 1456551 
6. Level 6 (110%) 5.5 50 55.505 1601136 
7. Level 7 (120%) 6.0 50 60.551 1754536 
8. Level 8 (150%) 7.5 50 75.688 2196599 
 
 
 
           Fig. 5 Linearity of Eletriptan hydrobromide 
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Table: 28 Linearity report of Eletriptan hydrobromide 
S.NO Parameter Values 
1. Linearity range 25% -150% 
2. Regression equation y = 29,193.2694x - 16,433.0727 
3. Correlation coefficient 0.9999 
4. Intercept 16,433.0727 
5. Slope 29,193.2694 
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Linearity Level-1 (25%) 
 
Fig. 6 Chromatogram of linearity at 25µg/ml  
Linearity Level-2 (50%) 
 
                     Fig. 7  Chromatogram of linearity at 50µg/ml 
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Linearity Level-3 (80%) 
 
                    Fig.8 Chromatogram of linearity at 80µg/ml 
Linearity Level-4(90%) 
 
                    Fig.9  Chromatogram of linearity at 90µg/ml 
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Linearity Level-5 (100%) 
 
                     Fig.10  Chromatogram of linearity at 100µg/ml 
Linearity Level-6 (110%)
 
                       Fig.11  Chromatogram of linearity at 110µg/ml 
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Linearity Level-7 (120%) 
 
                        Fig.12  Chromatogram of linearity at 120µg/ml 
Linearity Level-8 (150%)
 
                        Fig.13  Chromatogram of linearity at 150µg/ml 
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5.2.3 Assay 
Table: 29 Assay report of formulation of Ele HBr 
Formulation 
(Tablet) 
Label 
claimed  
(mg) 
Peak Area 
Mean± SD 
(N=3) 
Amount 
found (µg) 
Mean± SD 
%Recovery % 
RSD 
Eletriptan 
hydrobromide 
40mg 1485452.4±381
3.6625 
100.6 ± 
1.633 
100.6 1.62 
5.2.4 Accuracy and Range 
Table: 30 Recovery report of Eletriptan hydrobromide. 
S.No: Conc 
level 
Amt 
added 
(ppm) 
Amount 
found        
(ppm) 
%Recovery 
 
Mean 
 
SD 
 
%RSD 
1 25%-1 12.37 12.29 99.4 
99.5 0.231 0.23 2 25%-2 12.37 12.29 99.4 
3 25%-3 12.34 12.32 99.8 
4 50%-1 24.57 24.41 99.3 
99.6 0.306 0.31 5 50%-2 24.59 24.47 99.5 
6 50%-3 24.59 24.56 99.9 
7 100%-1 49.12 49.34 100.4 
100.7 0.945 0.94 8 100%-2 49.13 49.13 100.0 
9 100%-3 49.15 50.03 101.8 
10 150%-1 73.66 75.04 101.9 
100.6 1.153 1.15 11 150%-2 73.68 73.48 99.7 
12 150%-3 73.67 73.79 100.2 
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Recovery Level-1(25%) 
 
                       Fig.14. 25% Accuracy 
Recovery Level-2(50%) 
 
                       Fig.15 50% Accuracy 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 min
0
5
10
15
20
25
30
mV
Detector A:225nm 
E
le
tr
ip
ta
n
/5
.2
3
1
/2
4
6
1
5
5
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 min
0
25
50
75
100
mV
Detector A:225nm 
E
le
tr
ip
ta
n
/5
.3
2
2
/9
9
5
2
8
0
72 
 
Recovery Level-3(100%) 
 
                        Fig: 16. 100% Accuracy 
Recovery Level-4(150%)
 
                        Fig: 17. 150% Accuracy 
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5.2.5 Precision: 
a) Method Precision (Repeatability): 
Table: 31 Method Precision data 
Sample preparation % Assay Sample area 
1. 98.3 1447278 
2. 98.1 1446581 
3. 98.7 1455803 
4. 98.5 1451878 
5. 98.2 1445291 
6. 98.6 1452663 
Mean ± SD 98.4 ± 0.237 1449916 ± 3775.45 
%RSD 0.24 0.26 
 
c) Intermediate precision:  
Table: 32 Intermediate Precision data 
Sample preparation % Assay Sample area 
1. 99.0 1481560 
2. 98.5 1473785 
3. 98.5 1473762 
4. 98.3 1470233 
5. 98.7 1475723 
6. 98.4 1472640 
Mean ± SD 98.6 ± 0.229 1474617 ± 3511.403 
%RSD 0.23 0.24 
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Table: 33 Report of precision for Eletriptan hydrobromide: 
S.NO Precision %RSD Acceptance 
criteria 
1. Method Precision 0.24 NMT 2% 
2. Intermediate precision 0.23 NMT 2% 
 
5.2.6. Specificity and selectivity 
 
                       Fig.18 chromatogram of placebo 
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                       Fig.19 chromatogram of diluents 
 
                 Fig.20 chromatogram mobile phase 
Minutes
0 1 2 3 4 5 6 7 8 9 10
V
o
lts
0
50
100
V
o
lts
0
50
100
 
DAD-A:225nm
Name
Retention Time
Minutes
0 1 2 3 4 5 6 7 8 9 10
V
o
lts
0
50
100
V
o
lts
0
50
100
 
DAD-A:225nm
Name
Retention Time
